Mohamad Kassar MD

Oncology•Dyer, IN

Physician

Join to View Full Profile

1001 Calumet AveDyer, IN 46311
Phone+1 219-924-8178
Fax+1 219-924-8179

Education & Training

Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
Damascus University Faculty of MedicineClass of 1999

Certifications & Licensure

IN State Medical License 2007 - 2025
IL State Medical License 2005 - 2011
CT State Medical License 2004 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry Start of enrollment: 2015 Nov 01
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

90 citations
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Matthew D. Galsky, Amir Mortazavi, Matthew I. Milowsky, Saby George, Sumati Gupta
Journal of Clinical Oncology. 2020-04-09
44 citations
MammaPrint guides treatment decisions in breast cancer: results of the IMPACt trial.
Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis G. Levine
BMC Cancer. 2020-01-31
21 citations
Outpatient high‐dose melphalan in multiple myeloma patients
Mohamad Kassar, Erin Medoff, Stuart Seropian, Dennis L. Cooper
Transfusion. 2007-01-01

Press Mentions

The US Oncology Network Continues to Grow, Enhancing Community Cancer Care by Welcoming Two More PracticesOctober 22nd, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Mohamad Kassar MD

Dr. Kassar is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.